I am not sure what he did exactly but I found this outdated info;
Prior to joining Galapagos Genomics, he was Group Leader and Senior Scientist at IntroGene, now Crucell NV (Nasdaq, CRXL) where he ran research projects on the development of stem cell gene therapies for Gaucher disease using retroviral vectors and phage display technologies. He is a key inventor of the Galapagos functional genomics platform (US patent 6,340,595 others pending, Nat. Biotechnology 20(11): 1154-7) and the adenoviral siRNA technology SilenceSelectTM (W

3020931A1, 2; Genome Research 13: 2325-2332) and started Galapagos with CEO Onno van de Stolpe. He is currently responsible for the research at the Dutch site of Galapagos in Leiden that includes target discovery and validation for osteoarthritis and upper airway hyper-responsiveness, GPCRs and external alliances programs. As a postdoctoral fellow at the Montreal General Hospital, McGill University he worked on drug resistance of malaria, after receiving his PhD in Medicine from the University of Amsterdam in the laboratory of Dr. Ronald Oude Elferink and Professor Guido Tytgat. During his PhD period he worked on UDP-glucuronosyltransferases in particular their deficiency in the Crigler Najjar syndrome a form of hereditary unconjugated hyperbilirubinemia.
-----
It's not my field but I am doing computational fluid dynamics for my master's here in delft, I have not applied statistics yet in modelling flows but I am sure I am going to need it for turbulence modelling.
In the last paper you use bayesian statististics to create a physical model ?